Last reviewed · How we verify

buspirone+alprazolam

Seoul National University Hospital · FDA-approved active Small molecule

This combination pairs a serotonin 5-HT1A receptor agonist (buspirone) with a benzodiazepine GABA-A receptor agonist (alprazolam) to enhance anxiolytic effects through dual pathways.

This combination pairs a serotonin 5-HT1A receptor agonist (buspirone) with a benzodiazepine GABA-A receptor agonist (alprazolam) to enhance anxiolytic effects through dual pathways. Used for Anxiety disorders (generalized anxiety disorder, panic disorder), Short-term anxiety management.

At a glance

Generic namebuspirone+alprazolam
SponsorSeoul National University Hospital
Drug classAnxiolytic combination (azapirone + benzodiazepine)
Target5-HT1A receptor (buspirone); GABA-A receptor (alprazolam)
ModalitySmall molecule
Therapeutic areaPsychiatry / Neurology
PhaseFDA-approved

Mechanism of action

Buspirone selectively binds to serotonin 5-HT1A receptors, modulating serotonergic neurotransmission to reduce anxiety without sedation or muscle relaxation. Alprazolam enhances GABAergic inhibitory neurotransmission by potentiating GABA-A receptors, producing rapid anxiolytic, sedative, and muscle-relaxant effects. The combination leverages both mechanisms for broader anxiety symptom coverage.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: